Home > Publications database > Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high-grade serous ovarian cancer. > print

001     309981
005     20260220160020.0
024 7 _ |a 10.1002/1878-0261.70227
|2 doi
024 7 _ |a pmid:41714116
|2 pmid
024 7 _ |a 1574-7891
|2 ISSN
024 7 _ |a 1878-0261
|2 ISSN
037 _ _ |a DKFZ-2026-00407
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bielesch, Sophia
|0 0009-0005-6038-2914
|b 0
245 _ _ |a Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high-grade serous ovarian cancer.
260 _ _ |a Hoboken, NJ
|c 2026
|b John Wiley & Sons, Inc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771599605_3240618
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a High-grade serous ovarian cancer (HGSOC) is the most prevalent and lethal subtype of epithelial ovarian cancer (EOC), characterised by extensive peritoneal metastasis. The intermediate filament keratin 19 (KRT19) has been linked to tumour progression and chemoresistance in various cancers. However, its role varies across tumour types and remains unclear for HGSOC. We evaluated KRT19 protein expression in 199 HGSOC patients and correlated findings with clinical outcomes. In vitro, we assessed the effects of KRT19 on tumour-associated mechanisms, including proliferation, migration, adhesion, and spheroid formation. A xenograft mouse model was used to assess tumour burden in vivo. Publicly available datasets enabled in silico validation. KRT19 was significantly overexpressed in HGSOC, and high expression was associated with reduced overall survival. In vivo, KRT19-overexpression increased peritoneal tumour burden. In vitro and ex vivo, KRT19 induced a hybrid epithelial phenotype through enhanced epithelial-mesenchymal plasticity (EMP), promoting adhesion, migration, and spheroid integrity, thereby potentially supporting metastatic processes. Further, KRT19 could contribute to paclitaxel resistance. Altogether, KRT19 represents a potential independent prognostic marker and therapeutic target to inhibit metastatic dissemination.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a chemoresistance
|2 Other
650 _ 7 |a epithelial–mesenchymal plasticity
|2 Other
650 _ 7 |a keratin 19
|2 Other
650 _ 7 |a ovarian cancer
|2 Other
700 1 _ |a Vogel, Isabel
|b 1
700 1 _ |a Nokodian, Sina
|b 2
700 1 _ |a Moeller, Johanna
|b 3
700 1 _ |a Blechschmidt, Antonia
|b 4
700 1 _ |a Hecht, Vicky
|b 5
700 1 _ |a Kuentzel, Vanessa
|b 6
700 1 _ |a Thiedig, Katharina
|b 7
700 1 _ |a Schwab, Melissa
|b 8
700 1 _ |a Schilling, Oliver
|0 0000-0001-7678-7653
|b 9
700 1 _ |a Bronger, Holger
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Kiechle, Marion
|b 11
700 1 _ |a Magdolen, Viktor
|b 12
700 1 _ |a Dreyer, Tobias
|0 P:(DE-HGF)0
|b 13
773 _ _ |a 10.1002/1878-0261.70227
|g p. 1878-0261.70227
|0 PERI:(DE-600)2322586-5
|p nn
|t Molecular oncology
|v nn
|y 2026
|x 1574-7891
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2026
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:04:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:04:26Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2024-08-08T17:04:26Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-08-08T17:04:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL ONCOL : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOL ONCOL : 2022
|d 2025-01-07
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21